Braveheart Bio, Inc. (BRVE) Stock Price & Analysis
Braveheart Bio, Inc. (BRVE) is trading at USD 21.82, up 0.28% today, as of October 29, 2026 at 14:17 UTC (US market open; quotes may be delayed), according to Nexqual market data.
BRVE last closed at USD 21.76; today's session has ranged USD 21.45–22.2 on volume of 13,624 shares. Market capitalization is $1.96B, with a 52-week range of USD 17.86–32 (NGM). Source: Nexqual, retrieved October 29, 2026 at 14:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BRVE.md
Key facts (BRVE)
- Insider open-market purchases, last ~7 months: 8 Form 4 filings, $89.2M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 45.25 (range 40–48).
- Total return with dividends: 1Y -26.8% vs S&P 500 +13.1%; 5Y -27.3% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.44, revenue estimate $0K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BRVE)
Earnings yield -1.51%
Insider purchases (SEC Form 4, open-market, last ~7 months) (BRVE)
8 purchases, $89.2M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-07 | Ah Bio Fund Iv, L.P. | 1,100,000 | $19.8M | 18 | Too little history (no open-market trades in 2023–2025) | |
| 2026-08-07 | Forbion Growth Opportunities Fund Iii Cooperatief U.A. | 3,600,000 | $64.8M | 18 | Too little history (no open-market trades in 2023–2025) | |
| 2026-08-07 | Rickey James Paul | Chief Financial Officer | 27,777 | $500K | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Viehbacher Christopher | Director | 83,333 | $1.5M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Malek David I | Director | 4,166 | $75K | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Anderson Michele A. | Chief Development Officer | 1,111 | $20K | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Murdoch Travis | CEO and President | 83,333 | $1.5M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Lubner David Charles | Director | 55,555 | $1000K | 18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BRVE)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 45.25 (low 40, high 48).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Cantor Fitzgerald | Reiterated | Overweight | $40 |
Total return (dividends reinvested) (BRVE)
| 1Y (from 2026-08-06) | 5Y (from 2026-08-03) | |
|---|---|---|
| Total return | -26.8% | -27.3% |
| S&P 500 (SPY) | +13.1% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 82.2% | 83.7% |
| Max drawdown | -38.1% (Aug 2026→Oct 2026) | -37.6% (Aug 2026→Oct 2026) |
BRVE major shareholder filing: Schedule 13D/A, Sep 10, 2026
ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC filed a Schedule 13D/A with the SEC on Sep 10, 2026, reporting up to 13.50% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. …
Source: SEC EDGAR, Schedule 13D/A filed Sep 10, 2026. Quoted word for word; Nexqual adds no interpretation.
BRVE earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$2.51 | $2.69 | Miss −$5.20 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
BRVE recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 10, 2026 | Schedule 13D/A | ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC: 13.5% of shares, 5%+ holder that may seek to influence the company (amended) “The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in…” |
| Sep 8, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Sep 8, 2026 | 8-K | Quarterly results |
| Aug 18, 2026 | Schedule 13D | ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC: 17.2% of shares, 5%+ holder that may seek to influence the company “This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business…” |
| Aug 14, 2026 | Schedule 13D | AH Bio Fund IV, L.P., AH Equity Partners Bio IV, L.L.C.: 11.4% of shares, 5%+ holder that may seek to influence the company “The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of…” |
| Aug 14, 2026 | Schedule 13G | Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P.: 5.5% of shares, passive 5%+ holder |
| Aug 7, 2026 | 8-K | Bylaws or fiscal-year change |
| Jul 30, 2026 | S-1/A | Registration of new shares |
| Jul 15, 2026 | S-1 | Registration of new shares |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
BRVE company outlook (results filed Sep 8, 2026)
- “We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027.”
- “Based on the current operating plan, Braveheart Bio estimates that its existing cash and cash equivalents, together with the net proceeds from its IPO, will be sufficient to fund its projected operating expenses and capital expenditure requirements into 2029.”
- “These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of BHB-1893 and other product candidates, including the initiation, timing, progress, results and future data releases of ongoing and planned clinical trials; the timing of initiation as well as expected results from the NOBLEHEART-HCM global Phase 3 trial;”
Quoted word-for-word from the SEC 8-K results press release.
BRVE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.44 | $0.00 | −$0.44 | $0 | 5 |
| Next quarter (ends Dec 2026) | $-0.28 | $0.00 | −$0.28 | $0 | 5 |
| Current fiscal year (ends Dec 2026) | $-1.78 | $0.00 | −$1.78 | $0 | 5 |
| Next fiscal year (ends Dec 2027) | $-1.62 | $0.00 | −$1.62 | $0 | 5 |
Key Statistics (as of October 29, 2026 at 14:26 UTC)
| Price | USD 21.82 |
|---|---|
| Change | ▲ 0.28% (up) |
| Previous Close | USD 21.76 |
| Open | USD 21.55 |
| Day Range | USD 21.45 – 22.2 |
| 52-Week Range | USD 17.86 – 32 |
| Volume | 13,624 shares |
| Market Cap | $1.96B |
| Exchange | NGM |
Technical Analysis (BRVE)
Nexqual's technical model rates BRVE "SELL" based on 2 bullish and 4 bearish signals across 60 daily candles, as of October 29, 2026 at 14:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.24 (neutral) |
| vs SMA50 | Below (USD 23.65) |
| MACD | -0.42 (negative) |
Analyst Ratings (BRVE)
Wall Street analysts rate BRVE "Buy" based on 5 analysts, with a mean price target of USD 45.25 (range USD 40–48), per Nexqual as of October 29, 2026 at 14:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 45.25 |
| High Target | USD 48 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (BRVE)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.51 vs est 2.69 ▼ miss |
Source: Nexqual, October 29, 2026 at 14:26 UTC.
Financials & Fundamentals (BRVE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 13.63 |
| Total Cash | $122.83M |
| Total Debt | $575,000 |
Source: Nexqual, October 29, 2026 at 14:26 UTC.
Financial Health Score (BRVE)
Nexqual rates Braveheart Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 14:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $123M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$24M (TTM) |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -23.4% (last 4 quarters, SEC) |
Ownership (BRVE)
| Insider Ownership | +58.16% |
|---|---|
| Institutional Ownership | +28.12% |
| Shares Outstanding | 90.04M |
| Float | 12.72M |
Source: Nexqual, October 29, 2026 at 14:26 UTC.
Leadership (BRVE)
Braveheart Bio, Inc. is led by Travis Murdoch B.S., M.D., M.Sc., CEO, President & Director, per Nexqual as of October 29, 2026 at 14:26 UTC.
| CEO, President & Director | Travis Murdoch B.S., M.D., M.Sc. |
|---|---|
| Chief Financial Officer | James Paul Rickey |
| Chief Scientific Officer | Marc Evanchik M.S. |
| Director of Corporate Development | Timothy Y. Zhou |
| Associate Director of Human Resources & Office Manager | Steph Palencia |
Major Backers & Investors (BRVE)
Notable institutional backers of Braveheart Bio, Inc. include Fidelity, SmallCap World Fund Inc, MFS SERIES TRUST I-MFS New Discovery Fund, according to Nexqual as of October 29, 2026 at 14:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 3.45% |
| SmallCap World Fund Inc | 2.52% |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.38% |
Source: Nexqual, October 29, 2026 at 14:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 97.76 | ▲ 1.86% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 322.34 | ▲ 1.12% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 10.38 | ▼ 29.91% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 45.66 | ▲ 1.68% |
| AXSM | Axsome Therapeutics, Inc. | USD 146.77 | ▲ 2.27% |
| ABVX | Abivax SA | USD 91.84 | ▲ 2.23% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 14:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt